Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ranolazine Clear all
Terminated Not applicable Interventional Results available

The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

NCT01705509
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Ranolazine
Drug
Lead sponsor
Cardiovascular Institute of the South Clinical Research Corporation
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Not applicable Interventional

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

NCT01480336
View directory record Official record
Conditions
Arrhythmia
Interventions
Amiodarone Plus Ranolazine, Amiodarone with Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

NCT02147834
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Jul 22, 2026, 10:39 AM EDT
Not listed Phase 4 Interventional

Study to Reduce Symptoms of Premature Beats With Ranolazine

NCT01996618
View directory record Official record
Conditions
Premature Ventricular Beats
Interventions
Ranolazine
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041
View directory record Official record
Conditions
Atherosclerotic Coronary Vascular Disease
Interventions
Ranolazine 500 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

NCT00644332
View directory record Official record
Conditions
Chronic Angina
Interventions
Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine Implantable Cardioverter-Defibrillator Trial

NCT01215253
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Jul 22, 2026, 10:39 AM EDT
Not listed No phase listed Observational

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

NCT01804543
View directory record Official record
Conditions
Angina, Heart Disease
Interventions
Ranolazine
Drug
Lead sponsor
Westside Medical Associates of Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

NCT03472950
View directory record Official record
Conditions
ALS
Interventions
Ranolazine 500 MG, Ranolazine 1000 MG
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Targeting the Right Ventricle in Pulmonary Hypertension

NCT01839110
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

NCT01757808
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 72 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 22, 2026, 10:39 AM EDT
Not listed Phase 4 Interventional

Ranolazine, Ethnicity and the Metabolic Syndrome

NCT01304095
View directory record Official record
Conditions
Coronary Artery Disease, Angina, Metabolic Syndrome
Interventions
Ranolazine
Drug
Lead sponsor
Atlanta Heart Specialists, LLC
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cumming, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 4 Interventional

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

NCT02156336
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Jul 22, 2026, 10:39 AM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 22, 2026, 10:39 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Jul 22, 2026, 10:39 AM EDT